

*Subj*  
*A3*

bovine diarrhea virus comprising at least one plasmid that contains and expresses *in vivo* in a bovine host cell nucleic acid acid molecule(s) having sequence(s) encoding bovine diarrhea virus E2 protein, or C, E1 and E2 proteins, or E1 and E2 proteins.

13. The immunogenic composition according to claim 12 which comprises a plasmid that contains and expresses *in vivo* in a bovine host cell a nucleic acid molecule having a sequence encoding bovine viral diarrhea virus E2 protein.

14. The immunogenic composition according to claim 12 which comprises a plasmid that contains and expresses *in vivo* in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding bovine viral diarrhea virus E1 and E2 proteins.

15. The immunogenic composition according to claim 12 which comprises a plasmid that contains and expresses *in vivo* in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding bovine viral diarrhea virus C, E1 and E2 proteins.

16. A method for inducing an immunological response in a bovine comprising: administering to said bovine a vaccine selected from the group consisting of a live whole vaccine, an inactivated whole vaccine, a subunit vaccine, and a recombinant vaccine; and thereafter, administering to said bovine an immunogenic or vaccine composition as claimed in any one of claims 12-15 or 17-18.

17. A method for inducing an immunological response in a bovine comprising administering to said bovine an immunogenic or vaccine composition as claimed in any one of claims 12-16 or 18.


18. A kit comprising (i) an immunogenic composition according to any one of claims 12-17, and (ii) a bovine vaccine selected from the group consisting of a live whole vaccine, an inactivated whole vaccine, a subunit vaccine, and recombinant vaccine.--

Entry of this Preliminary Amendment and an early examination of claims 12-18 on the merits are respectfully requested. It is believed that no additional fees are due for entry and consideration of this Preliminary Amendment and related papers. Any deficiency or overpayment in this fee, or any other fee occasioned by this paper or any overpayment in any other fee occasioned by this paper, may be charged or credited to Deposit Account No. 50-0320.

An early and favorable examination on the merits is respectfully requested.

Respectfully submitted,  
FROMMER LAWRENCE & HAUG LLP

By:

  
\_\_\_\_\_  
Thomas J. Kowalski  
Reg. No. 32,147  
(212) 588-0800

U.S. PATENT AND TRADEMARK OFFICE